There are 15,358 results relating to "Medicin Viagra-m"
Order by
|
Questions and Answers
Date answered:
30 June 2010
S3W-34671
Paid Value of Claims Paid £m No. of claims Received but Not Paid Estimated Value of Unpaid Claims £m RP Annual Recurrent 2009 1,150 537 £3.70 613 £4.61 RP Capital (to date) 2,452 1,991 £35.30 ...
Questions and Answers
Date answered:
22 November 2007
S3W-06166
To ask the Scottish Executive whether it considers (a) Additional Support for Learning support, (b) additional support needs in-service training, (c) additional support staff, (d) additional teachers for early years, (e) alternatives to exclusion, (f) continuing professional development, (g) Curriculum for Excellence, (h) discipline, (i) GLOW, (j) integration in school education, (k) inclusion, (l) job sizing, (m...
Questions and Answers
Date answered:
1 December 2009
S3W-29102
In addition, the patient information leaflet supplied with the medicine provides information about the medicine including any side effects.
Questions and Answers
Date answered:
21 January 2008
S3W-08005
Before a medicine can be placed on the UK market it must have marketingauthorisation from either the MHRA or the European Medicines Agency (EMEA).
Official Report
Meeting date:
26 November 2020
Meeting of the Parliament (Hybrid) 26 November 2020
Earlier this week, the bank confirmed that its first investment will be in a company called M Squared Lasers Ltd, to advance further its research and development.
Questions and Answers
Date answered:
12 December 2008
S3W-18464
To ask the Scottish Executive what information it has on plans to license new products for the treatment of the varroa mite in bee populations. The regulation of veterinary medicines is a reserved matter. Responsibility for authorising the marketing of veterinary medicinal products in the UK rests with Defra''s Veterinary Medicines Directorate (VMD).
Last updated:
3 December 2019
$name
uri=CELEX:32000L0031&qid=1574347034051&fro m=EN 9 Available at http://www.legislation.gov.uk/uksi/2002/2013/contents/made. 10 See section 6 of the 2013 Act, available at http://www.legislation.gov.uk/ukpga/2013/26/contents/enacted. 11 See section 7(9) of the 2013 Act. 12 See paragraph 1.12 of the Commission’s Discussion Paper. 4 This document relates to the...
Official Report
Meeting date:
17 November 2009
Public Petitions Committee, 17 Nov 2009
They give the SMC increased flexibility that can be applied to any new medicine that it is appraising, not just cancer medicines and end-of-life medicines.
Questions and Answers
Date answered:
20 January 2010
S3W-30692
It is not within the remit of the Scottish Chemotherapy Advisory Group to assess geographical variations in the use of Scottish Medicines Consortium approved drugs. The remit of the group is to ensure that cancer medicines are delivered within a safe and quality assured framework.
Questions and Answers
Date answered:
24 October 2007
S3W-05426
To ask the Scottish Executive what its policy is for the use of Alfamax on fish farm sites and whether it proposes to amend the policy in light of the treatment having successfully passed the requirements of the EU’s mutual recognition system for medicines used in EU waters. The regulation ofveterinary medicines is a reserved matter and is the responsibility of theVeterinary Medicines Directorate (VMD).ScottishGovernment policy is supportive of the use of the sea lice medicine Alphamaxonce marketing authorisation in the UK has been granted.The treatment has recently been granted a full marketing authorisation in Norway, which is an essential first step in applying formutual recognition in the UK.It is up to thecompany concerned to submit an application for mutual recognition to the VMDand we have encouraged them to do so.
